Objetivo Prediction-ADR aims to discover the genetic factors predisposing patients to adverse drug reactions (ADRs) from cardiovascular disease (CVD) drugs. This will be achieved by assembling a consented blood bank and DNA for a population of ~500 cases of ACEi induced angioedema and statin induced myopathy defined using a standardised phenotypic criteria. An innovative next generation sequencing strategy will be used to find predisposing genetic changes to myopathy and angioedema. Our SME partner will use proprietary software to build a highly predictive genetic algorithm for subsequent performance evaluation in real world clinical datasets involving >50,000 patients. This will deliver a novel set of genomic biomarkers to improve effective prevention or treatment of CVD providing the EU SME competitive advantage in the emerging personalised medicine market. The number of CVD drug prescriptions globally means that the absolute number of adverse drug reactions (ADRs) is substantial resulting in harm to the patients and leading to discontinuation and increased risk of CVD progression. Genome wide association studies (GWAS) has recently accelerated the progress in determining genetic biomarkers for adverse responses to drugs and with the advent of affordable whole genome sequencing, genetic research is now positioned to accelerating it even further. This provides a new opportunity to discover improved genomic biomarkers for extreme phenotypes of severe ADRs. The ultimate goal is to have these markers accepted by EMA and FDA and to disseminate these findings not only to the scientific community but also to lay people and patient organisations. This genetic algorithm will be developed into a commercially available clinical test by Asper Biotech. As 7 Million individuals were treated with statins in the UK alone during 2012, the size of the potential market for this test is immense. Ámbito científico medical and health sciencesclinical medicinecardiologycardiovascular diseasesmedical and health sciencesbasic medicinepharmacology and pharmacyadverse drug reactionsnatural sciencesbiological sciencesgeneticsgenomes Programa(s) FP7-HEALTH - Specific Programme "Cooperation": Health Tema(s) HEALTH.2013.4.2-2 - Adverse drug reaction research Convocatoria de propuestas FP7-HEALTH-2013-INNOVATION-1 Consulte otros proyectos de esta convocatoria Régimen de financiación CP-FP - Small or medium-scale focused research project Coordinador UNIVERSITY OF DUNDEE Aportación de la UE € 762 664,00 Dirección Nethergate DD1 4HN Dundee Reino Unido Ver en el mapa Región Scotland Eastern Scotland Angus and Dundee City Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo Vicki Gilbert (Mrs.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos Participantes (6) Ordenar alfabéticamente Ordenar por aportación de la UE Ampliar todo Contraer todo UNIVERSITEIT UTRECHT Países Bajos Aportación de la UE € 507 838,00 Dirección HEIDELBERGLAAN 8 3584 CS Utrecht Ver en el mapa Región West-Nederland Utrecht Utrecht Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo R. De Kok-Baan (Mrs.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos THE UNIVERSITY OF LIVERPOOL Reino Unido Aportación de la UE € 640 801,00 Dirección BROWNLOW HILL 765 FOUNDATION BUILDING L69 7ZX Liverpool Ver en el mapa Región North West (England) Merseyside Liverpool Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo Jenny Lawson (Ms.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos UPPSALA UNIVERSITET Suecia Aportación de la UE € 632 604,00 Dirección VON KRAEMERS ALLE 4 751 05 Uppsala Ver en el mapa Región Östra Sverige Östra Mellansverige Uppsala län Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo Mikael Widell (Mr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos PHARMACOGENOMIC INNOVATIVE SOLUTIONS LIMITED La participación finalizó Reino Unido Aportación de la UE € 22 645,39 Dirección ASTON COURT KINGSMEAD BUSINESS PARK HP11 1LA HIGH WYCOMBE BUCKS Ver en el mapa Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Contacto administrativo Alun Mccarthy (Dr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos ASPER BIOTECH AS Estonia Aportación de la UE € 158 382,00 Dirección VAKSALI 17A 50410 TARTU Ver en el mapa Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Contacto administrativo Anu Aaspõllu (Dr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos ADORIAL TECHNOLOGIES LTD Reino Unido Aportación de la UE € 275 017,61 Dirección ASTON COURT KINGSMEAD BUSINESS PARK HP11 1LA HIGH WYCOMBE Ver en el mapa Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Contacto administrativo Alun Mccarthy (Dr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos
